The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...

The stock's fall snapped a three-day winning streak.